Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells.

doi:10.1016/s0022-3565(24)38187-x

Paper

DOI: 10.1016/s0022-3565(24)38187-x

Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells.

Published May 1, 1999 · Ryuta Yamazaki, S. Kawai, Tsuneo Matsumoto

The Journal of pharmacology and experimental therapeutics

Q2 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Aceclofenac and 4'-hydroxyaceclofenac reduce prostaglandin E2 production in rheumatoid synovial cells by inhibiting cyclooxygenase, facilitating their anti-inflammatory effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/S0014-2999(98)00078-8

Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells.

Different NSAIDs show varying degrees of selectivity for cyclooxygenase-1 and -2, potentially impacting their pharmacological profiles and clinical use.

1998·128citations·S. Kawai et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/S0014-2999(97)89179-0

Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors.

Aceclofenac is a novel non-steroidal anti-inflammatory drug that is intracellularly converted into cyclooxygenase inhibitors, effectively inhibiting prostaglandin E2 production in inflammatory cells.

1997·80citations·Ryuta Yamazaki et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/s0090-9556(25)07491-4

Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human.

Aceclofenac metabolism varies species-dependently, with 4'-hydroxyaceclofenac being the major metabolite in humans and rat livers, and its stability affecting its hydrolysis and oxidative metabolism.

1996·36citations·R. Bort et al.·Drug metabolism and disposition: the biological fate of chemicals

Drug metabolism and disposition: the biological fate of chemicals

DOI: 10.1016/s0090-9556(25)07441-0

Metabolism of aceclofenac in humans.

Aceclofenac is metabolized in human hepatocytes and microsomes to form the major metabolite, with cytochrome 2C9 playing a key role in its in vivo metabolism.

1996·75citations·R. Bort et al.·Drug metabolism and disposition: the biological fate of chemicals

Drug metabolism and disposition: the biological fate of chemicals

DOI: 10.1016/0005-2760(95)00026-9

Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2.

Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce prostaglandin synthesis without affecting COX2 mRNA levels, making macrophages a useful model for studying COXI and COX2.

1995·60citations·C. Tordjman et al.·Biochimica et biophysica acta

Biochimica et biophysica acta

Citations

DOI: 10.5114/reum.2018.76816

Diclofenac in the treatment of pain in patients with rheumatic diseases

Diclofenac is highly effective in treating pain and physical disability in rheumatic diseases, but safety considerations are crucial when selecting dosage forms and application methods.

2018·41citations·J. Kołodziejska et al.·Reumatologia

Reumatologia

DOI: 10.1016/j.xphs.2017.04.046

Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1.

Suramin is a potent selective inhibitor of the prostaglandin transporter OATP2A1, providing comprehensive information about drugs in clinical use that interact with OATP2A1.

2017·17citations·Shunsuke Kamo et al.·Journal of pharmaceutical sciences

Journal of pharmaceutical sciences

DOI: 10.3109/10717544.2016.1155244

Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation

Phospholipid-based vesicles, particularly ethosomes, can enhance the delivery and safety of aceclofenac by topical route, offering a promising new therapeutic approach for pain and inflammation.

2016·48citations·Gajanand Sharma et al.·Drug Delivery

Drug Delivery

DOI: 10.1155/2014/406731

Topical Delivery of Aceclofenac: Challenges and Promises of Novel Drug Delivery Systems

Topical delivery of aceclofenac (ACE) is a promising method to reduce gastrointestinal side effects and improve safety in osteoarthritis treatment, but requires further research and development.

2014·92citations·Kaisar Raza et al.·BioMed Research International

BioMed Research International

DOI: 10.1185/03007995.2013.795139

Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis

Aceclofenac is better tolerated and as effective as diclofenac for treating knee osteoarthritis, with less gastrointestinal side effects and less need for gastroprotective agents.

2013·32citations·A. Pareek et al.·Current Medical Research and Opinion

Current Medical Research and Opinion